(v) HVR-H2 comprising sequence E1-E18, wherein E1-E18 is GEILPGGGDTNYNEIFKG (SEQ ID NO: 135) and

(vi) HVR-H3 comprising sequence F1-F10, wherein F1-F10 IS TRRVPVYFDY (SEQ ID NO: 136).

41. The use according to any one of claims 34 to 40, the CD79b antibody-drug conjugate having the formula Ab-(L-D)p, wherein

(a) Ab is the CD79b antibody of claim 40;

(b) L is a linker;

(c) D is a drug moiety.

42. The use according to any one of claims 34 to 41, the CD79b antibody-drug conjugate having the formula Ab-(L-D)p, wherein L is selected from 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (val-cit), alanine-phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N-Succinimidyl 4-(2-pyridylthio) pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1 carboxylate (SMCC), and N-Succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB).

43. The use according to any one of claims 34 to 42, the CD79b antibody-drug conjugate having the formula Ab-(L-D)p, wherein D is selected from the group consisting of auristatin, dolostantin, DM1, DM3, DM4, MMAE and MMAF.

44. The use according to any one of claims 34 to 43, wherein the CD79b antibody-drug conjugate is anti-CD79b-MC-vc-PAB-MMAE.

45. The use according to any one of claims 34 to 44, wherein the anti-CD79b antibody in said CD79b antibody-drug conjugate is huMA79b.v28.

46. The use according to any one of claims 34 to 45, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are administered.

~~47. The invention as herein before described.~~